ProCE Banner Activity

HAVEN 2: Second Interim Analysis of Phase III Single-Arm Study of Emicizumab in Pediatric Patients With Hemophilia A and Factor VIII Inhibitors

Slideset Download
Conference Coverage
Emicizumab prevented or reduced bleeding episodes requiring treatment and was well tolerated by this pediatric population.

Released: December 12, 2017

Expiration: December 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation